ERBB2 and neoplasm: The American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines have clearly defined intra-tumor heterogeneity of HER2 amplification (i.e., HER2/CEP17 signal ratios >2.2 in 5%–50% of the neoplastic cells).